SCHEMBL29377307

SCHEMBL29377307

COc1cc(C(C)=O)c(OC)cc1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.58
FYN P06241 1/20 0.58
HTT P42858 1/20 0.55
CYP3A4 P08684 2/20 0.50
ALDH1A1 P00352 2/20 0.47
CA9 Q16790 1/20 0.46
TSHR P16473 1/20 0.44
RAB9A P51151 2/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17749683 1.00 LCK (0.58) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL16462717 0.92 CYP3A4 (0.50) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL20630769 0.87 HTT (0.68) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL7112806 0.86 LCK (0.71) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL5786372 0.86 LCK (0.78) LCKFYNCYP3A4ALDH1A1CA9
SCHEMBL22117016 0.85 LCK (0.50) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL3308874 0.83 LCK (0.49) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL7891214 0.83 HTT (0.50) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL30350316 0.83 CYP3A4 (0.69) LCKFYNHTTCYP3A4ALDH1A1
SCHEMBL7457674 0.83 CYP3A4 (0.69) LCKFYNHTTCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294538-A1 Serotonin Receptor Agonists and Methods of Making and Using the Same KULEON LLC (US) 2024-09-05 US disclosed
CN-117015536-A 2- (indazol-5-yl) -6- (piperidin-4-yl) -1, 7-naphthyridine derivatives and related compounds as modulators of nucleic acid splicing and treatment of proliferative diseases 雷密克斯医疗公司 2023-11-07 CN disclosed
EP-4192454-A1 COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2023-06-14 EP disclosed
CN-116171153-A Compositions for modulating splicing 斯基霍克疗法公司 2023-05-26 CN disclosed
CN-116003409-A Substituted pyrrolopyridines as bromodomain inhibitors 基因泰克公司 2023-04-25 CN disclosed
CN-107207493-B Substituted pyrrolopyridines as bromodomain inhibitors 基因泰克公司 2023-01-20 CN disclosed
CN-115583947-A Substituted pyrrolopyridines as bromodomain inhibitors 基因泰克公司 2023-01-10 CN disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
WO-2022031838-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294538-A1 Serotonin Receptor Agonists and Methods of Making and Using the Same HTR1A, HTR7, HTR3A LCK 2913/4885FYN 3530/4885HTT 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.